Inhibition of NaV1.8 prevents atrial arrhythmogenesis in human and mice
Authors:
Open Access
- 20 February 2020
- journal article
- research article
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 115 (2) , 1-14
Abstract
Pharmacologic approaches for the treatment of atrial arrhythmias are limited due to side effects and low efficacy. Thus, the identification of new antiarrhythmic targets is of clinical interest. Recent genome studies suggested an involvement of SCN10A sodium channels (NaV1.8) in atrial electrophysiology. This study investigated the role and involvement of NaV1.8 (SCN10A) in arrhythmia generation in the human atria and in mice lacking NaV1.8. NaV1.8 mRNA and protein were detected in human atrial myocardium at a significant higher level compared to ventricular myocardium. Expression of NaV1.8 and NaV1.5 did not differ between myocardium from patients with atrial fibrillation and sinus rhythm. To determine the electrophysiological role of NaV1.8, we investigated isolated human atrial cardiomyocytes from patients with sinus rhythm stimulated with isoproterenol. Inhibition of NaV1.8 by A-803467 or PF-01247324 showed no effects on the human atrial action potential. However, we found that NaV1.8 significantly contributes to late Na+ current and consequently to an increased proarrhythmogenic diastolic sarcoplasmic reticulum Ca2+ leak in human atrial cardiomyocytes. Selective pharmacological inhibition of NaV1.8 potently reduced late Na+ current, proarrhythmic diastolic Ca2+ release, delayed afterdepolarizations as well as spontaneous action potentials. These findings could be confirmed in murine atrial cardiomyocytes from wild-type mice and also compared to SCN10A−/− mice (genetic ablation of NaV1.8). Pharmacological NaV1.8 inhibition showed no effects in SCN10A−/− mice. Importantly, in vivo experiments in SCN10A−/− mice showed that genetic ablation of NaV1.8 protects against atrial fibrillation induction. This study demonstrates that NaV1.8 is expressed in the murine and human atria and contributes to late Na+ current generation and cellular arrhythmogenesis. Blocking NaV1.8 selectively counteracts this pathomechanism and protects against atrial arrhythmias. Thus, our translational study reveals a new selective therapeutic target for treating atrial arrhythmias.Keywords
Funding Information
- Else Kröner-Fresenius-Stiftung
- Deutsche Gesellschaft für Innere Medizin
- Universitätsklinikum Regensburg (Reform A, Reform C, Reform C)
- Deutsche Stiftung für Herzforschung
- Marga und Walter Boll-Stiftung
- Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
- Deutsche Forschungsgemeinschaft (SFB1002)
This publication has 34 references indexed in Scilit:
- The Functional Consequences of Sodium Channel NaV1.8 in Human Left Ventricular HypertrophyESC Heart Failure, 2018
- Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial FibrillationPLOS ONE, 2015
- Genome- and Phenome-Wide Analyses of Cardiac Conduction Identifies Markers of Arrhythmia RiskCirculation, 2013
- Enhanced Sarcoplasmic Reticulum Ca 2+ Leak and Increased Na + -Ca 2+ Exchanger Function Underlie Delayed Afterdepolarizations in Patients With Chronic Atrial FibrillationCirculation, 2012
- Re-Evaluation of the Action Potential Upstroke Velocity as a Measure of the Na+ Current in Cardiac Myocytes at Physiological ConditionsPLOS ONE, 2010
- Altered Na+Currents in Atrial FibrillationJACC, 2010
- Genetic variation in SCN10A influences cardiac conductionNature Genetics, 2010
- Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillationHeart Rhythm, 2008
- Resurgence of Sodium Channel ResearchAnnual Review of Physiology, 2001
- The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathwaysNature Neuroscience, 1999